Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 277 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lung Diseases, Pulmonary Embolism
Interventions
Magnetic Resonance Angiography, Magnetic Resonance Venography
Procedure
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
1,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Atlanta, Georgia • Bethesda, Maryland • Rockville, Maryland + 5 more
Completed Not applicable Interventional Results available

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

NCT06062329
Conditions
Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Interventions
Symphony Thrombectomy System
Device
Lead sponsor
Imperative Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 15 more
Conditions
Pulmonary Embolism
Interventions
Augmented pulse oximetry using incentive spirometer., Incentive spirometer.
Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Covid19
Interventions
rNAPc2, Heparin
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Conditions
Tissue Plasminogen Activator
Interventions
early tPA and DNase
Combination Product
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Pancreas Cancer, DVT, Pulmonary Embolism
Interventions
Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 3 Interventional Results available

PREVENTion of Clot in Orthopaedic Trauma

NCT02984384
Conditions
Blood Clot, Trauma
Interventions
Acetylsalicylic acid, Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years and older
Enrollment
12,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Tucson, Arizona • Miami, Florida • Indianapolis, Indiana + 16 more
Conditions
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
Interventions
Retrospective Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Conditions
Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Conditions
Pulmonary Embolism Subacute Massive
Interventions
Walking test
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Fondaparinux
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pulmonary Embolism
Interventions
VenaTech Convertible Vena Cava Filter, Vena Cava Filter Conversion
Device · Procedure
Lead sponsor
B. Braun Interventional Systems, Inc
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • Hinsdale, Illinois + 8 more
Conditions
Acute Pulmonary Embolism
Interventions
Endobronchial ultrasound (EBUS)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Conditions
Venous Thromboembolism, Pulmonary Embolism, DVT
Interventions
Rivaroxaban, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
41,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Completed Phase 2 Interventional Results available

Nitric Oxide to Treat Pulmonary Embolism

NCT01939301
Conditions
Pulmonary Embolism
Interventions
Inhaled Nitric Oxide, Sham
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana • Jackson, Mississippi
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more